Raw Materials Brand Ranking

Jiangsu Yabang Pharmaceutical Group Co., Ltd.

Jiangsu Yabang Pharmaceutical Group Co., Ltd. was founded in 2002 and is headquartered in Changzhou City, Jiangsu Province. It is a large comprehensive pharmaceutical group integrating new drug research and development, raw material production, pharmaceutical preparation production and pharmaceutical circulation. The current employees are more than 2,000 and the total assets are more than 1 billion yuan. At present, the group is centered on Jiangsu Yabang Pharmaceutical Group Co., Ltd., and owns Yabang Pharmaceutical Co., Ltd., Jiangsu Yabang Johnson Pharmaceutical Co., Ltd., Jiangsu Yabang Epson Pharmaceutical Co., Ltd., and Jiangsu Yabang Shengyuan Pharmaceutical Co., Ltd. 6 wholly-owned subsidiaries including Co., Ltd., Changzhou Yabang Pharmaceutical Co., Ltd., Changzhou Yabang Pharmaceutical Research Institute Co., Ltd. After years of scientific research and innovation, Yabang Pharmaceutical has now formed a high-tech specialty covering anti-infective drugs, cardiovascular and cerebrovascular drugs, respiratory and immune system drugs, and has 7 major series, nearly 20 dosage forms, and more than 200 specifications. Product group. A marketing network covering 29 provinces (cities), 40 regions and more than 1,000 marketers across the country has been established.

Sichuan Kelun Pharmaceutical Co., Ltd.

Founded in 1996, Kelun has now formed a "Pin"-shaped architecture operation platform composed of Kelun Pharmaceutical, Chuanning Biotechnology and Kelun Botai, with a total market value of over 100 billion yuan. In 2018, Kelun was named "Manufacturing Single Champion Demonstration Enterprise" for his global advantages in large-capacity injections. Sichuan Kelun Pharmaceutical Co., Ltd. was successfully listed on the Shenzhen Stock Exchange in June 2010, and immediately launched the 10 billion industry investment plan and began to implement the development strategy of "three-in-one developments, innovative growth". The first engine maintains Kelun's leading position in the infusion field through continuous industrial upgrading and variety structure adjustment; the second engine builds from intermediates, raw materials to preparations through innovative development and utilization of high-quality natural resources. The third engine accumulates the ultimate driving force for the everlasting enterprise foundation through the construction of the R&D system and diversified technological innovation. In the field of infusion, Kelun has achieved comprehensive industrial upgrading, and has the profitability of both high-end manufacturing and new materials, occupying a strategic high ground for technological innovation and quality benchmarks. Columbia has established a closed responsibility system from drug research and development, production and manufacturing, logistics and transportation to terminal use to ensure product quality and safety. The leading products have been exported in batches and enjoy a high reputation in more than 50 countries and regions. The stand-up bag® independently developed by Kelun is the first at home and abroad. It has more than 20 patents and has won the National Science and Technology Progress Award. It has higher safety and cost-effectiveness than traditional infusions, and has great application value in reducing energy consumption and environmental protection, representing the direction of development of Chinese infusion products. In the field of antibiotics, the company has established Yili Chuanning Biotechnology Co., Ltd. to produce erythromycin thiocyanate and cephalosporin series intermediates. Through R&D testing, upgrading and optimization, innovative cooperation, and the introduction of advanced domestic and foreign technology equipment, Sichuan Ning has been approved to build a National Environmental Protection Antibiotic Bacterial Slag Harmless Treatment and Resource Utilization Engineering Technology Center, solving the source problems of the antibiotic industry. In December 2022, Chuanning Biotech was successfully listed on the Shenzhen Stock Exchange GEM and entered the field of synthetic biology. Kelun has applied for more than 1,300 invention patents and obtained more than 700 invention patents. He has launched the development of more than 500 major drugs in many diseases such as tumors, bacterial infections, parenteral nutrition, etc.; since 2017, it has been approved for marketing every year. More than 20 items have become the leading generic drug enterprise in China, and has become the leading supplier of national centralized drug procurement with a winning rate of nearly 90%. At the same time, more than ten innovations are used to treat major diseases such as tumors, autoimmunity, inflammation, and metabolism. The drug project is in its clinical stage, with multiple clinical trials being a global multi-center research. Multiple projects work together with European and American partners to deploy global clinical research and are carried out simultaneously in multiple countries including China and Europe and the United States to achieve the synergy of pipelines and technology platforms. Effects, maximize the global value of pipelines.

Zhejiang Xianju Pharmaceutical Co., Ltd.

Zhejiang Xianju Pharmaceutical Co., Ltd. (stock code: 002332) was formerly the Xianju Pharmaceutical Factory. It was founded in 1972. The company has fulfilled the corporate mission of "your health and happiness, my sincerity and responsibility" to "become the whole world. The top ten steroid drug suppliers have become popular among customers and employees. "For the development vision, they focus on the field of steroid hormones. The company's total share capital is RMB 989.204866 million, and currently has more than 3,600 employees. The company is a key high-tech enterprise in the National Torch Program, and has a Zhejiang Steroid Drug Engineering Technology Research Center and a national postdoctoral workstation. Ranked 67th on the top 100 Chinese pharmaceutical industry enterprises in 2020. The company has unique products and adheres to the integrated business model of raw materials and preparations. Its main business is the development, production and sales of steroidal raw materials and preparations. Product research and development closely focuses on the four major therapeutic areas (gynecology, anesthesiology, respiratory and dermatology). The company has established long-term cooperative relationships with more than 20 well-known domestic scientific research institutes (schools) including the Shanghai Institute of Organics of the Chinese Academy of Sciences, Zhejiang University, and China Pharmaceutical University, recruited senior scientific research talents, and gradually connected with international new drug development. The company has initially formed a technical architecture system with professional foreign R&D institutions as the source, Hangzhou and Xianju Research Institutes as the digestion and acceptance, and Xianju Base as the implementation. The company's subsidiaries include 20 wholly-owned and controlled subsidiaries including Taizhou Xianju Pharmaceutical Co., Ltd. It has three core manufacturing platforms in China: Xianju Yangfu Raw Materials Production Zone, Xianju Yangfu Preparation Production Zone, and Linhai South Sichuan Production Zone. It has two standardized Raw Materials Factory abroad, mainly based on its Italian subsidiary NewChem. Xianju Pharmaceutical advocates real culture, win-win culture and innovative culture, and upholds the core corporate values ​​of "integrity, hard work, openness, learning, responsibility, and win-win". The company adheres to the strategic concept of achieving win-win results in customers, enterprises, employees, society, etc., and advocates the value concept that personal value is reflected in the process of realizing corporate value and social value. In the future development process, the company will continue to improve the management level of the enterprise, continuously develop high-tech products, give full play to the scale effect, promote the high-quality development of the enterprise, and contribute to the cause of human health.

Xilong Scientific Co., Ltd.

Xilong Science Co., Ltd. (hereinafter referred to as "Xilong Science", stock code: 002584), formerly known as Xilong Chemical Co., Ltd., was founded in 1983 and was listed on the Shenzhen Stock Exchange in June 2011. It was the earliest listing in China. chemical reagent company. The company is mainly engaged in the research and development and production of fine chemicals and new materials including general chemical reagents, chemical reagents for PCB, ultra-clean high-purity chemical reagents, wet electronic chemicals, raw materials, food additives, photovoltaic electrode materials, lithium battery positive electrode materials and other fine chemicals and new materials. Sales and supporting services. The business areas cover industry, agriculture, health, environmental protection, teaching, scientific research, biology, life sciences, electronics, military industry, aerospace, coatings, printing and cosmetics, medical care, and health. It has developed into a super-large professional manufacturer and integrated supplier with strong R&D capabilities, wide sales coverage and leading comprehensive supporting scale in China.

Nanjing Chemical Reagent Co., Ltd.

Nanjing Chemical Reagent Co., Ltd. (formerly Nanjing Chemical Reagent Factory) was established in 1958. In 2004, the company was restructured and established in the "Three Links" and implemented the shareholding reform in 2015 and listed on the New Third Board (Securities abbreviation: Nanjing Reagent, stock code: 833179 ). The company is a high-tech enterprise engaged in the research and development, production, sales and technical services of various reagents, pharmaceutical excipients and customized chemicals. The company is located in Nanjing Jiangbei New Materials Science and Technology Park, covering an area of ​​72,000 square meters, with an annual production capacity of 35,000 tons, and currently has more than 200 employees. The company has more than 10,000 varieties and specifications, and is widely used in scientific research in universities, inspection and monitoring institutions, as well as biopharmaceuticals, food and beverages, electronic information, petrochemicals, aerospace and military industry, new energy, new materials and other national economic development fields. The products are exported to Europe, the United States and Southeast Asia. The company is committed to lean management and maintaining the effective operation of ISO9001, ISO14001, GB/T28001 and safety standardized management systems. The company has established industry, academia and research cooperation relationships with many universities, undertakes national, ministry and provincial scientific and technological research tasks many times, and has obtained 35 national patent authorizations. On August 8, 2015, the "Nanjing Reagent" e-commerce platform was officially launched. By integrating enterprise information resources, customers can meet real-time inquiries about product information, maintain communication with customers through telephone and online communication, and realize online self-service orders and Seamless connection of offline delivery experience. The needs of customers are the pursuit of Nantes. Nantes team will continue to listen and respond to customers, attach importance to the multi-dimensional needs of users, and wholeheartedly provide customers with high-quality products and multi-faceted services.

NHU Co., Ltd.

Zhejiang Xinhecheng Co., Ltd. was founded in 1999 and was listed in 2004 (stock code 002001). Since its establishment, the company has always adhered to the concept of innovation-driven development and growth in market competition, focusing on the research, development, production, sales and services of functional chemicals such as nutritional products, spices, polymer materials, etc., and has been used in more than 100 countries and regions around the world. Our customers provide comprehensive solutions in the fields of nutrition, health, daily chemical care, transportation, environmental protection, energy, etc., and continuously improve human life quality with high-quality, healthy, green and low-carbon products to create sustainable value for stakeholders.

DSM (China) Co., Ltd.

The Royal Dutch DSM Group, with over 118 years of history, is a mission-oriented science company with 23,000 employees worldwide, active in nutrition, health and green living. DSM believes that the mission of contemporary and future generations to create a better life. DSM believes that achieving sustainable development means pursuing balanced development of economic benefits, environmental quality and social responsibility at the same time, that is, creating value in three aspects: human, earth environment and profit. DSM’s business unit develops and delivers innovative scientific solutions for nutrition, health and green living every day to benefit the entire planet and all of humanity. DSM’s business group is divided into: Nutrition, Materials and Innovation Centers according to its products and markets. Nutrition includes DSM nutrition products (animal nutrition and health, human nutrition and health, personal care and fragrance ingredients and pharmaceutical solutions), DSM Food Ingredients Technology and DSM Hydrophilic Colloids. The material consists of DSM engineering materials and DSM protective materials. Innovation Center develops DSM’s emerging business areas (EBA): Biomedical and Bio-based products and services.

Guangdong Zhaoqing Xinghu Biotechnology Co., Ltd.

Guangdong Zhaoqing Xinghu Biotechnology Co., Ltd. (hereinafter referred to as the "Company") was a former agricultural microbial pharmaceutical factory established in 1964. It was converted to MSG in 1981 and converted from the former Zhaoqing MSG factory to establish a joint-stock company in 1992. It is a pilot project of shareholding reform in Guangdong Province. One of the companies. Listed on the Shanghai Stock Exchange in August 1994, with the stock abbreviation of "Xinghu Technology", stock code: 600866. In April 2009, Guangdong Guangxin Holding Group Co., Ltd. (hereinafter referred to as "Guangxin Group") acquired Zhaoqing State-owned Assets The state-owned controlling stake in Xinghu Technology held by the commission has become the controlling shareholder of the company. In 2019, the company acquired Sichuan Jiuling Pharmaceutical Technology Co., Ltd. In 2022, the company will acquire Ningxia Yipin Biotechnology Co., Ltd. The company's main products include food additives, feed additives, pharmaceutical raw materials and intermediates, organic fertilizers, bio-based new material products, etc. The company is a high-tech manufacturing enterprise with biofermentation and chemical synthesis as its core, and is a listing platform for the main business sectors of biopharmaceuticals and food health under Guangxin Group. The company mainly focuses on food additives, feed additives, pharmaceutical intermediates and raw materials, and its products cover many fields such as food processing, feed processing, and pharmaceutical health. Relying on the production bases of Yinchuan, Ningxia and Chifeng, Inner Mongolia, the company has achieved industrial layout in the northwest region and is positioned as a production base for bulk amino acid products; relying on the production bases of Daqing and Zhaodong, Heilongjiang to strengthen the company's layout advantages in the northeast region and is positioned as a new bio-fermentation product and high-end Production base for products and new materials; the Southwest Sichuan base is located at the research and development and production base for pharmaceutical intermediates and raw materials. The company has more than ten high-level technology research and development platforms, including "National Certified Enterprise Technology Center", "Postdoctoral Research Mobile Workstation", "Guangdong Province Doctoral Workstation", "Guangdong Province Key Engineering Technology Center", "Guangdong Province Amino Acid Engineering Technology Center", and other high-level technology research and development platforms. It is Guangdong Province The organizational unit of the Microbial Manufacturing Health Industry Technology Innovation Alliance. The company has obtained national high-tech enterprises, national torch plan key high-tech enterprises, national torch plan outstanding high-tech enterprises, Guangdong Province technological innovation advantage enterprises, Guangdong Province innovative enterprises, Guangdong Province independent innovation benchmark enterprises, Guangdong Province independent innovation demonstration enterprises, Honors such as Guangdong Province Integrity Demonstration Enterprise. The holding subsidiary Yipin Bio has been recognized as a national enterprise technology center, a national technological innovation demonstration enterprise, a national key leading enterprise in rural industrialization, a national intellectual property demonstration enterprise, an advanced feed enterprise in the international cooperation of the "Belt and Road" and a top 500 private enterprises in China's manufacturing industry. , science and technology innovation team and other honors.

Sovereign Specialty Chemicals (Shanghai) Co., Ltd.

SI Group is a global leader in innovative technologies for performance additives, process solutions, active pharmaceutical ingredients and chemical intermediates. SI Group ’s solutions are critical to many different industries and applications, creating remarkable results. SI Group drives value by improving the quality, performance, and durability of countless items SI Group uses every day. SI Group is an organization of approximately 2,000 people that drives change with a passion for safety, chemistry and extraordinary achievements.

Northeast Pharmaceutical Group Co., Ltd.

Northeast Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Northeast Pharmaceutical", stock code: 000597) is a listed company under Liaoning Fangda Group Industrial Co., Ltd. (hereinafter referred to as "Fangda Group"). The company was formerly the Northeast Pharmaceutical General Factory. It was founded in 1946. It has assisted in the construction of 52 pharmaceutical enterprises in 19 provinces and cities across the country, and has transported more than 1,300 cadres to the outside world. It is known as the cradle of my country's national pharmaceutical industry. At present, Northeast Pharmaceutical has major business segments such as chemical raw materials, chemical preparations, pharmaceutical commerce, pharmaceutical engineering, and biomedicine, covering the entire industrial chain of pharmaceutical research and development, manufacturing, and distribution. It has an employee team of more than 8,500 people and a total assets of 12 billion yuan. The company mainly produces vitamin series drugs, anti-infection system drugs, obstetrics and gynecology system drugs, digestive system drugs, urinary system drugs, antiviral series drugs, cardiovascular and cerebrovascular series drugs, analgesic and cough-relieving series drugs, biological diagnosis series, big health There are ten series of fine products including the field series, as well as more than 400 chemical raw materials, pharmaceutical intermediates and preparation products. The leading products are exported to more than 100 countries and regions. The company has a strong product manufacturing system. The preparation production base covers an area of ​​180,000 square meters, has more than 30 production lines, and an annual production capacity of 10 billion pieces (branches, pills, pellets, pellets, and bottles). The raw materials production base covers an area of ​​910,000 square meters. It is a national intelligent manufacturing demonstration factory for bulk raw materials and pharmaceutical intermediates. Its main products include vitamin C and series, L-carnitine series, Fosfomycin series, piracetam, and Kaprinline. Methyl esters, adamantine, sulfaluminum, berberine, chloramphenicol, etc. are fully extended to the downstream Northeast pharmaceutical preparation industry chain, forming a comprehensive competitive advantage that is difficult to replicate. The company has a national advanced environmental protection treatment system to achieve all-round treatment of sewage, exhaust gas, noise and solid waste. The treatment capacity of the raw materials and drug sewage treatment system reaches 50,000 cubic meters per day. The incinerator can handle 9,000 tons of hazardous waste throughout the year, and exhaust emissions meet EU standards. The circular economy industrial park realizes resource processing of production waste and turns waste into treasure. Northeast Pharmaceuticals has a complete quality management system, and its product quality complies with the new GMP, EP, USP, JP, BP, CP and other quality standards. Many products have successively passed international certifications such as EDQM, FDA, Japan Ministry of Health and Welfare, BRC, HALAL, KOSHER, etc. The leading products have passed the registration and quality audits in many countries and regions such as the United States, Europe, Japan, Brazil, Russia, and Poland. Northeast Pharmaceutical is not only an important drug production and export base in China, but also has independent business companies such as drug research institutes, engineering design companies, equipment manufacturing and installation companies, international trading companies, metrology and testing companies, and hazardous chemical transportation companies, including 5. Our family is a high-tech enterprise. The Northeast Pharmaceutical and Pharmaceutical Business Network covers all prefecture-level cities and counties in Liaoning and extends to the three northeastern provinces. The Northeast Pharmacy has more than 100 chain stores, and the pharmaceutical e-commerce business has achieved online and offline integration, and business model innovation continues to be promoted.

CSPC Pharmaceutical Group Limited

Shiyao Group Ouyi Pharmaceutical Co., Ltd. is a comprehensive large-scale enterprise mainly focusing on internationalization and industrialization of new products. It covers an area of ​​about 346 acres and has about 3,000 employees. The company's production scope covers seven therapeutic areas, more than 400 preparation products and more than 20 chemical synthetic raw materials, and is equipped with internationally advanced "Bosch", "Fett", "Urman", "GEA", " IMA” and other automated production lines, with a comprehensive annual production capacity of 15 billion tablets of solid preparations and an annual production capacity of 1,500 tons of raw materials. The main preparation products include Xuanning, Olaining, Domesso, Keli, Abidol Hydrochloride Tablets, etc. ;The main raw materials include azithromycin, indomethacin, levamlodipine maleate, tramadol hydrochloride, imatinib methanesulfonate, etc. Ouyi Pharmaceutical has established a complete three-level quality management system. All drug production lines have passed the new version of GMP certification. Three workshops have passed the "zero defect item" to pass the US FDA certification, and seven workshops have passed the official certification of WHO, Colombia, Peru, etc. A total of 3 CEP certificates and 4 DMF registration numbers were obtained; 10 varieties have entered the US market; 61 varieties, including azithromycin tablets, tramadol hydrochloride tablets, and 83 product specifications have passed the evaluation of the quality and efficacy consistency of generic drugs. The company has established complete second-level and third-level R&D institutions, equipped with internationally advanced large-scale analytical instruments; has complete sets of equipment required for a complete small-scale, intermediate-level and amplified production of three-level R&D platforms; has 71 authorized invention patents, PCT International application; in recent years, the company's new products have been launched one after another, among which Oulaining, Xuanning, Ouyi, Weihong, Qingre Detox Soft Capsules, Gubang and other varieties have achieved good economic benefits, and Qingre Detox Soft Capsules It is listed as a protected variety of traditional Chinese medicine by the state. The company has a sales network across the country. The market share of Ouyi, Vienna, Chimait, Gubang, Cefladine, Norfloxacin and other products ranks first among similar varieties in the country. The products are sold to Europe, Africa, Southeast Asia, and South America. As well as more than 100 countries and regions including Japan, it has now become a designated production enterprise for famous buyers in countries such as the Netherlands and Switzerland. Looking to the future, Ouyi Pharmaceutical will adhere to the corporate mission of "making good medicine, serving China, and repaying the world with good rewards", practice the manufacturing concept of "strict, meticulous and fast, craftsmanship and intelligent manufacturing", and use more, newer and better quality. Products contribute to society!

Zhuhai United Laboratories Co., Ltd.

Federal Pharmaceutical was founded in 1990 and listed in Hong Kong in 2007. The stock code is 3933.HK, mainly engaged in the research and development, production and sales of drugs. After more than 30 years of development, Federal Pharmaceutical has formed a comprehensive pharmaceutical group with four major business segments: preparations, raw materials, biology, and animal welfare, and nine production and R&D entities. Its sales network covers the world and currently has more than 16,000 employees. Since its establishment, Federal Pharmaceuticals has been committed to providing high-quality products and services to the society and promoting high-quality development of the pharmaceutical industry. It is one of the leading comprehensive pharmaceutical companies in China. Zhuhai Federal Pharmaceutical Co., Ltd. was registered and established in 1993. The factory was completed and put into production in 1998. Currently, production bases have been established in Sanzao Town and Nanshui Town, Jinwan District, Zhuhai City, covering a total area of ​​450,000 square meters and employees are about 2,700. people. After more than 20 years of development, it has become a high-tech modern comprehensive pharmaceutical enterprise integrating production and R&D. The company's main products include more than 50 varieties of insulin, penicillin, cephalosporin, carat, and penem. Oral semi-synthetic penicillin workshop is currently a production workshop with a large production capacity of similar products in China, with an annual production capacity of more than 5,000 tons. The annual production capacity of the "Golden Feiyan" and "Silver Feiyan" brand products of the cephalosporin series and the carat series are about 1,000 tons. Products sold worldwide. Federal Pharmaceuticals is a company that uses genetically engineered Pichia cerevisia expression technology to produce insulin products, and is also a company that has an insulin prefilled pen assembly line in China. In 2009, the second generation of insulin human insulin (Yusling) was launched. In 2016, the third generation of insulin analog insulin glargine (Yusling) was launched. In 2021, the insulin aspart was launched, and Federal Pharmaceutical became the same. Domestic companies with second and third generation insulin production capabilities. After the project reaches full production, the production capacity will reach 3 tons of raw materials and 300 million preparations, with an annual output value of more than 10 billion yuan. Introducing intelligent manufacturing, Zhuhai Company is an enterprise that adds sterile operation robot intervention system to the sterile raw material industry. It uses robots instead of manual operation in A-level clean areas to ensure the quality of sterile drugs and reduce safety risks. The explored intelligent manufacturing has a profound impact on the quality assurance of sterile pharmaceuticals and the application of industrial intelligence. Taking a diversified development path, Federal Peptide Beauty is a company that has created a polypeptide cosmetic raw material brand for skin care. Its main effects include whitening, firming, anti-wrinkle and anti-aging. In 2017, the use of peptide raw materials into finished cosmetics began, opening a new era of federal peptide beauty skin care. In line with the international level, the quality system insists on international capacity building, and Zhuhai Company always puts quality work first. All series of products such as insulin and antibiotics have passed the domestic GMP compliance test. Amoxicillin and ampicillin raw materials have been subjected to German GMP certification inspections many times. Amoxicillin sodium, potassium clavulanate and other sterile raw materials have obtained the EU CEP certificate, and sterile raw materials such as ampicillin sodium and sulbactam sodium Together, we have successively passed the official joint GMP inspections of EDQM and Spain and other officials. In the future, Federal Pharmaceutical will continue to promote industrial upgrading and innovative development, develop more safe and effective drugs, and make greater contributions to human health.

North China Pharmaceutical Group Corporation

North China Pharmaceutical Group Co., Ltd. (hereinafter referred to as Hua Pharmaceutical Group) is located in Shijiazhuang, the capital of Hebei Province. The predecessor of North China Pharmaceutical Factory was a key construction project during China's "First Five-Year Plan" period. It was started in June 1953 and completed and put into production in June 1958. It has created a history of large-scale antibiotic production in my country, and has been used for the development of human health and the national pharmaceutical industry. It has made important contributions to changing the situation of shortage of doctors and drugs in my country. In 1992, it was reorganized and established North China Pharmaceutical Co., Ltd., and was listed on the Shanghai Stock Exchange in 1994 (stock name: North China Pharmaceutical 600812). In January 1996, North China Pharmaceutical Factory was officially reorganized into a wholly state-owned company - North China Pharmaceutical Group Co., Ltd. In June 2009, with the approval of the Hebei Provincial Government, Jizhong Energy Group implemented a restructuring of Hua Pharmaceutical Group. Over the years, Huayao Group has adhered to the corporate purpose of "human health first, quality always comes first", continuously innovated, operated steadily, gradually expanded its business scope, maintained excellent development performance, and its main economic and technical indicators have always been at the forefront of the domestic industry. . As of the end of 2018, Huayao Group had a total assets of 20.6 billion yuan, nearly 15,000 employees, and more than 40 subsidiaries (branches) companies, including the National Engineering Research Center for Microbial Drugs, the National Key Laboratory for Antibody Drug Development, Antibiotic Enzyme Catalysis and Crystallization technology, the three innovative platforms of the National and Local Joint Engineering Laboratory, mainly include nearly a thousand product specifications in the fields of chemical pharmaceuticals, modern biotechnology drugs, vitamins and nutritional health products, modern Chinese medicine, biological agricultural and veterinary medicine, etc. The treatment field covers anti-infection categories , cardiovascular, kidney disease, anti-tumor and immunomodulation, etc. The process routes and production layout of the main production units are all designed and implemented in accordance with the current European and American versions and the new Chinese version of GMP standards, and have a modern pharmaceutical production platform with international advanced standards.

Anqiu Lu'an Pharmaceutical Co., Ltd.

After more than 40 years of development, Anqiu Luan Pharmaceutical Co., Ltd. currently has a total assets of 1.6 billion yuan, more than 1,400 employees, covering an area of ​​600 mu, and an annual main business income of 1 billion yuan. It is a production and operation of chemical raw materials. Paracetamol, DC-grade paracetamol ( direct tableting level, introducing advanced one-step granulation equipment, producing various products of different specifications according to customer requirements ), tablets (aluminum magnesium carbonate chewable tablets, paracetamol tablets, etc.) and other products. Modern pharmaceutical companies. Among them, the annual production capacity of paracetamol is 40,000 tons, and the annual production capacity of DC-grade paracetamol is 12,000 tons. The annual production capacity of paracetamol tablets is 4 billion tablets. Products such as paracetamol have passed the certification of the US FDA (Food and Drug Administration) and the EU EDQM (European Drug Quality Administration). More than 80% of the products are exported to the United States, the United Kingdom, Germany, France, Brazil, South Africa, India, Japan and other 100 global products. Many countries and regions.

Jinzhou Jiutai Pharmaceutical Co., Ltd.

Jinzhou Jiutai Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical company with a production history of more than 70 years. The predecessor, Jinzhou Pharmaceutical Factory, was first established in 1951 and was reorganized into Jinzhou Jiutai Pharmaceutical Co., Ltd. in 1998. It is one of the key pharmaceutical companies in Liaoning Province. The company covers an area of ​​58,000 square meters, has a registered capital of 40.46 million yuan, and currently has 1,250 employees, including 310 engineering and technical personnel. It has 5 production workshops, 1 R&D center, and 1 controlled pharmaceutical commercial company. The company has nearly 100 kinds of products, and the "chlorhexidine" raw materials are domestic manufacturers. The suppository products that use it as raw materials have formed a series of products covering the whole country; solid preparation products have formed two series of antipyretic analgesics and digestive system drugs. ; Powder injection "pantoprazole sodium for injection" is a four-category new drug in the country, and has good effect in treating peptic ulcers. The company's gynecological medicine is the "gynecological medicine production base" designated by the former State Administration of Medicine. The company's product structure is reasonable and its economic operation is good. Advanced production technology, mature process routes, complete quality monitoring system, stable and reliable product quality. Jiutai Pharmaceutical Company is a provincial enterprise technology research and development center. Over the years, the company has successfully developed chlorhexidine, maloteester, omeprazole sodium, pantoprazole sodium, betastine hydrochloride, ethylenediamine diacetamide acetate, polyhexamethylenebiguanide hydrochloric acid There are more than a dozen preparations such as salt (PHMB) and three-flavor hemorrhoid suppositories, chlorhexidine suppositories, metronidazole furazolidone suppositories (Jiutai Kunbao), azithromycin fumarate capsules. Four major series of products represented by chlorhexidine raw materials, gynecological suppositories, anti-peptic ulcer drugs, and antipyretic analgesics. In recent years, in accordance with the spirit of deepening the reform of state-owned enterprises, Jiutai Pharmaceutical has vigorously promoted mechanism innovation, management and technological innovation, and led the overall situation with innovative work. In July 2011, the company carried out asset restructuring, further optimized the structure of various resource elements of the enterprise, accelerated the innovation of the enterprise, fully utilized the potential of the enterprise and employees, and improved the production efficiency and competitiveness of the enterprise. Maintain the long-term development of the enterprise. In order to improve the production technology level and the development of new products, the company has gathered outstanding pharmacy talents from China Pharmaceutical University, Shenyang Pharmaceutical University, Jiamusi Medical College and other universities, and has successively introduced advanced production from Japan, the United Kingdom, Italy and other countries. equipment. In the business field, the company takes "user first" as its purpose and "sincere and friendly, mutual benefit and win-win" as its starting point, paying attention to contracts and keeping trustworthy. The company has a capable sales team and a solid sales network. Products are sold all over the country, and some are sold to Europe and the United States.

Shandong Xinhua Pharmaceutical Co., Ltd.

Shandong Xinhua Pharmaceutical Co., Ltd. was established in 1943 in Jiaodong Anti-Japanese Base Area. It is an early chemical synthetic pharmaceutical enterprise in New China. It is an important global production and export base for antipyretic analgesics and painkillers. It is an important domestic cardiovascular and anti-infection. Manufacturers of nervous system, steroid hormone drugs, etc. It has four major business segments: chemical raw materials, pharmaceutical preparations, pharmaceutical intermediates, and e-commerce business, 5 industrial parks and 14 subsidiaries. The annual production capacity of chemical raw materials is 50,000 tons, 500,000 tons of pharmaceutical intermediates, 32 billion solid preparations (particles), and 1.5 billion injections. The annual export volume is nearly US$400 million, and it has established long-term strategic cooperative relations with more than 200 well-known multinational companies including Roche, Bayer, and Bailey. Xinhua Pharmaceutical is a listed company in H-share and A-shares. Xinhua Pharmaceutical is a national high-tech enterprise, a key high-tech enterprise of the National Torch Plan, and a backbone enterprise of the National Torch Plan biopharmaceutical industry base. It has a national enterprise technology center, and has academician workstations, postdoctoral workstations, Taishan industrial talent positions, Taishan scholar positions, There are six major talent platforms including the Master's Joint Training Point and Shandong Technician Workstation. In recent years, Xinhua Pharmaceutical has increased its school-enterprise cooperation efforts and established comprehensive strategic cooperative relations with the Chinese Academy of Medical Sciences, Tsinghua University, Shandong University, Shenyang Pharmaceutical University, Qingdao University of Science and Technology, etc. Six centers including the Medicinal Chemistry Research Center and the Drug Preparation Research Center have been built, covering 12 directions including digestive system, pain control, cardiovascular and cerebrovascular system, anti-metabolic system, nervous system, nutritional health, hormones, etc. , increase R&D investment and lay out more than 100 new products. A total of 21 products and 27 specifications have passed consistency evaluation, and have 8 national first-class new drug documents and 21 second-class new drug documents and obtained 266 authorized patents. It is a three-star "Chinese Patent Shandong Star Enterprise". Xinhua Pharmaceutical's quality value of "product quality is related to the life of the enterprise, and drug quality is related to the life of the person" has been thoroughly implemented by all employees and throughout the process. The company focuses on quality investment and has established a quality control system for the entire process from the entry of raw materials into the factory and the production link to the exit of the product. In the 1990s, Xinhua Pharmaceutical won the domestic "Excellent Quality Management Award". 23 products have won high-quality product awards at the provincial and ministerial levels and above, of which 3 products have won the national gold award and 3 products have won the national silver award. At present, all drugs in production in Xinhua Pharmaceutical have passed the national new version of GMP certification, and have obtained 22 US FDA registration documents, 12 EU EDQM documents, and 3 ANDA documents. Xinhua Pharmaceutical Modern Pharmaceutical International Cooperation Center has passed the China NMPA, GMP certifications such as the UK MHRA, the US FDA and the EU, the preparation products produced by the center are qualified to be sold to international markets such as Europe, the US and the UK, and have exported more than 5 billion tablets in total. In recent years, Xinhua Pharmaceutical has launched a batch of new drugs such as: National Class I innovative drugs, new non-hormonal anti-inflammatory and anti-allergic drugs----------------------------------------------------------------------------------- Shutaide (rabeprazole sodium enteric-coated tablets), Jiaheluo (glimediide tablets), the drug for treating cardiovascular and cerebrovascular treatment (aspirin enteric-coated sustained-release tablets), the National Class 3.1 new drug insurance Chang (Jocal calcium tablets), Fuya'an series three high-purity fish oil health products, and unique dosage form nimodipine sustained-release capsules, the main products are included in the national medical insurance catalog. As a state-owned holding enterprise with red gene, Xinhua Pharmaceutical has always adhered to the corporate mission of "protecting health and benefiting society" and actively fulfilled its social responsibilities. Especially in the three years of fighting the epidemic, Xinhua People do not uphold conditions, live up to their mission, and do their best to do their best. Production and supply of drugs. Especially since the adjustment of the epidemic prevention and control policy in December 2022, the national allocation task was successfully completed in just over 20 days, and a total of 800 million pieces of ibuprofen and other heat-relieving towns were supplied to 31 provinces (municipalities directly under the central government, autonomous regions) across the country. Pain drugs (most of the ibuprofen tablets in the Beijing market are supplied by Xinhua Pharmaceuticals) have effectively guaranteed the people's drug needs and truly reflected the responsibility of state-owned enterprises. The Ministry of Industry and Information Technology, Beijing, Tsinghua University, Fujian Province, Nanjing, Dalian, Yangzhou City and other cities have successively sent letters of condolences and thanks to Xinhua Pharmaceutical, giving high recognition and praise for Xinhua Pharmaceutical's full efforts to ensure the supply of key drugs for the epidemic. Over the years, the company has highlighted the connotation of quality, internationalization, science and technology and responsibility, and has created professional characteristics through all-round means, establishing a good image of quality Xinhua, international Xinhua, science and technology Xinhua and responsibility Xinhua. Xinhua Pharmaceuticals was listed in Shandong Province's first batch of "Honorable Shandong Business" five-star brand image list, and won the National Model Labor Relations Harmonious Enterprise, National Green Factory and Green Supply Chain Enterprise, China Quality Integrity Enterprise, Shandong Province All Staff Innovation Enterprise, Shandong The provincial talent work unit, the leading science and technology enterprise in Shandong Province, and the Shandong Province's advanced collective in fighting the new crown pneumonia epidemic are honored.

Zhuhai Runduo Pharmaceutical Co., Ltd.

Zhuhai Rundu Pharmaceutical Co., Ltd. is a modern technology-based pharmaceutical enterprise integrating drug research and development, production and sales. It is located in Jinwan District, Zhuhai City, Guangdong Province and was established in 1999. On January 5, 2018, the company was listed on the Shenzhen Stock Exchange (Securities abbreviation: Rundu Co., Ltd.; Stock code: 002923). The company currently has more than 1,300 formal employees (including wholly-owned subsidiaries). The company's main business is the research, development, production and sales of chemical preparations, chemical raw materials, and pharmaceutical intermediates. The product application scope covers peptic ulcers, hypertension, surgical anesthesia, antipyretic analgesia, anti-infection, diabetes and other products. field. The company has a complete quality management system and has established a drug production and manufacturing center strictly in accordance with the requirements of the national GMP. The existing product production lines (covering raw materials, tablets, capsules, preparation intermediates (micropellets), etc.) have passed the new national GMP version. Certification, some specialty raw material products have passed the official certification of the World Health Organization, the European Union, Japan, etc., and some products have passed the on-site inspection of the US FDA. While the company continues to maintain outstanding development of unique new dosage forms of drugs (micro-pill capsule preparation technology, micro-pill tableting preparation technology, etc.), enteric-coated and slow-release preparation technology, it actively develops the development of original innovative drugs and multiple varieties of drugs. Technology upgrade; gradually promote the vertical integration of raw materials to preparations; carry out diversified R&D models, strengthen cooperation with R&D institutions with complete domestic and foreign technology, develop a series of preparation products, promote the company's international trade, and gradually realize The company's internationalization strategy strives to build a domestic enterprise that produces special products such as micropill preparations, anti-hypertensive sartan drugs, anti-peptic ulcer proton pump inhibitors and other special products.

Shiyao Holdings Group Co., Ltd.

Shiyao Holding Group Co., Ltd. is a national innovative enterprise integrating the research and development, production and sales of innovative drugs. The total existing assets of the entire group are more than 58 billion yuan and have 28,000 employees. Hong Kong listed company (01093.HK) has entered the 100 billion market capitalization club and is a constituent stock of the Hang Seng Index. In 2019, the subsidiary Xinnowe (300765.SZ) was successfully listed on the GEM, and Shiyao Group achieved a new era of the "red chip + A" financing pattern. Currently, there are more than 10 pharmaceutical production bases in Hebei, Shanxi, Shandong, Jiangsu, Jiangxi, Tianjin and other provinces and cities. The product sales are spread to more than 100 countries and regions around the world, and 36 varieties have sales of more than 100 million yuan.

Boehringer Ingelheim (China) Investment Co., Ltd.

Boehringer Ingelheim is committed to researching breakthrough therapies aimed at transforming lives and protecting the health of generations. As a global leading pharmaceutical company driven by R&D, the company demonstrates value through innovation in areas where medical needs are highly unmet. Boehringer Ingelheim has been an independent family business since its establishment in 1885 and has always focused on long-term development. In the three major business areas of human medicine, animal health and biopharmaceutical contract production, more than 52,000 employees worldwide serve more than 130 regions.

Merck Investments (China) Co., Ltd.

Merck KGaA was founded in 1668 and has a history of about 350 years. It is headquartered in Darmstadt, Germany. It is mainly committed to innovative pharmaceuticals, life sciences and cutting-edge functional material technologies, and Technology is the driving force to create value for patients and customers. Merck began to engage in trade with China at the end of the 19th century, selling high-purity chemical reagents to China, and established a Chinese subsidiary in Shanghai in 1933. In China, Merck is mainly engaged in pharmaceutical, life sciences and chemical businesses, and provides customers with solutions from innovative prescription drugs, over-the-counter drugs to life sciences, effective pigments and chemicals for industrial purposes. Merck's business is mainly divided into four major branches: Merck Serono business branch, consumer health care business branch, Merck Millipo business branch, and functional materials business branch. Merck is a partner of China. Merck has a history of development in China for more than 80 years. China is an important strategic market for all Merck's business areas (including high-performance materials, life sciences and medical health); Merck has 3,200 employees in China (including Hong Kong and Macau); in Beijing, Shanghai, Hong Kong, Wuxi, Suzhou and Nantong has 20 corporate entities. Merck has many important investments in China. Recently, Merck's pharmaceutical, health and life sciences business in Nantong and its high-performance materials business in Shanghai have invested 170 million euros, 80 million euros and 44 million euros respectively. In addition, Merck has also set up a global biopharmaceutical R&D center in Beijing, a display material R&D center and a life science laboratory in Shanghai, and a lithographic material R&D center in Suzhou. China has become an important source of innovation for Merck.